MANUFACTURING

We are committed to manufacturing COVID-19 medicines and making them available.

- Biopharmaceutical researchers and scientists are working around the clock to meet the demands of COVID-19 vaccine development and manufacturing by continuing to study and expand the use of the current vaccines while bringing patients additional products to treat and prevent COVID-19.
- Prior to authorization, biopharmaceutical companies proactively planned and built manufacturing capacity to ensure that once COVID-19 vaccines were authorized or approved by the FDA, distribution could occur rapidly.
- Over 6.4 billion vaccine doses have been delivered as of October 2021.

EQUITY

The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.

- America’s biopharmaceutical companies are working with patients, community groups and policymakers to help address social determinants of health and to help drive proactive solutions that improve public health and individual patient health outcomes.
- We are committed to earning trust and helping to address systemic issues that deter minority communities from participating in clinical trials, so that people who want to participate can.

ADVANCING THE FIGHT TO BEAT COVID-19

Through research, scientists have discovered new ways to stimulate the immune system, which could be leveraged to help combat future viruses.

- Building on deep scientific knowledge gained from decades of experience with viruses such as SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress in advancing treatments and vaccines to help fight COVID-19. All of the vaccines that have received emergency use authorizations or FDA approval so far rely on groundbreaking platform technologies, meaning once a genetic target is identified from a new infectious agent (like COVID-19), the platform can be used to quickly create prototype vaccines to move into preclinical and clinical testing.
- To date, at least one vaccine is authorized for ages 12 and up with additional research and regulatory review underway for additional patient populations.
- The FDA has authorized innovative treatments, including monoclonal antibodies for treatment of certain patients with COVID-19. The FDA has also approved an antiviral medicine for the treatment of adult and pediatric patients requiring hospitalization for COVID-19.

Learn more at PhRMA.org/Coronavirus

As of October 2021

3 https://www.unicef.org/supply/covid-19-vaccine-market-dashboard